![Gilead Sciences, Inc. Website](https://cdn.finchat.io/29002.png)
Gilead Sciences, Inc.
NasdaqGS-GILD
Company Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Name
Gilead Sciences, Inc.
CEO
Mr. Daniel P. O'Day
Website
www.gilead.com
Sector
Biotechnology
Year Founded
1987
Profile
Market Cap
$98.01B
EV
$117.49B
Shares Out
1,244.99M
Revenue
$27.81B
Employees
18,000
Margins
Gross
77.44%
EBITDA
48.42%
Operating
38.5%
Pre-Tax
5.53%
Net
3.79%
FCF
24.8%
Returns (5Yr Avg)
ROA
5.83%
ROTA
-32.01%
ROE
17.98%
ROCE
20.2%
ROIC
15.79%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$83.5
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$3,781M
Net Debt
$19.57B
Debt/Equity
1.28
EBIT/Interest
10.97
Growth (CAGR)
Rev 3Yr
1.44%
Rev 5Yr
4.46%
Rev 10Yr
4.78%
Dil EPS 3Yr
-40.99%
Dil EPS 5Yr
-28.88%
Dil EPS 10Yr
-15.29%
Rev Fwd 2Yr
1.59%
EBITDA Fwd 2Yr
3.16%
EPS Fwd 2Yr
3.03%
EPS LT Growth Est
10.65%
Dividends
Yield
—
Payout
359.67%
DPS
$3.04
DPS Growth 3Yr
3.03%
DPS Growth 5Yr
4.84%
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
3.82%